QuantiFERON^®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity

References

• Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol. Blood Marrow Transplant.9(9), 543–558 (2003).
   PubMed Web of Science ®Google Scholar
• Hakki M, Boeckh M, Ljungman P. Cytomegalovirus infection after stem cell transplantation. In: Transplant Infections (3rd Edition). Bowden RA, Ljungman P, Snydman D (Eds). Lippincott Williams & Wilkins, PA, USA 311–327 (2010).
   Google Scholar
• Razonable RR, Limaye AP. Cytomegalovirus infection after solid organ transplantation. In: Transplant Infections (3rd Edition). Bowden RA, Ljungman P, Snydman D (Eds). Lippincott Williams & Wilkins, PA, USA 328–361 (2010).
   Google Scholar
• Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am. J. Transplant.6(2), 262–274 (2006).
   PubMed Web of Science ®Google Scholar
• Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am. J. Transplant.9(Suppl. 4), S78–S86 (2009).
   PubMed Web of Science ®Google Scholar
• Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med.340(19), 1462–1470 (1999).
   PubMed Web of Science ®Google Scholar
• Bando K, Paradis IL, Similo S et al. Obliterative bronchiolitis after lung and heart–lung transplantation. An analysis of risk factors and management. J. Thorac. Cardiovasc. Surg.110(1), 4–13 (1995).
   PubMed Web of Science ®Google Scholar
• George MJ, Snydman DR, Werner BG et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am. J. Med.103(2), 106–113 (1997).
   PubMed Web of Science ®Google Scholar
• Cantoni N, Hirsch HH, Khanna N et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol. Blood Marrow Transplant.16(9), 1309–1314 (2010).
   PubMed Web of Science ®Google Scholar
• Deayton JR, Wilson P, Sabin CA et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS14(9), 1163–1170 (2000).
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am. J. Transplant.4(6), 928–936 (2004).
   PubMed Web of Science ®Google Scholar
• Corales R, Chua J, Mawhorter S et al. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon? Transpl. Infect. Dis.2(3), 133–139 (2000).
   PubMedGoogle Scholar
• Doron S, Ruthazer R, Werner BG, Rabson A, Snydman DR. Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes. Transplantation81(5), 697–703 (2006).
   PubMedGoogle Scholar
• Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood103(6), 2003–2008 (2004).
   PubMed Web of Science ®Google Scholar
• Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med.143(12), 870–880 (2005).
   PubMed Web of Science ®Google Scholar
• Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am. J. Transplant.8(5), 975–983 (2008).
   PubMed Web of Science ®Google Scholar
• Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am. J. Transplant.8(1), 69–77 (2008).
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation89(7), 779–795 (2010).
   PubMed Web of Science ®Google Scholar
• Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am. J. Transplant.8(1), 158–161 (2008).
   PubMed Web of Science ®Google Scholar
• Manuel O, Venetz JP, Fellay J et al. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. Swiss Med. Wkly137(47–48), 669–676 (2007).
   PubMed Web of Science ®Google Scholar
• Wasserfallen JB, Kast-Bruckner M, Manuel O, Venetz JP, Meylan PR, Pascual M. Cost–effectiveness of a new combined immunosuppressive and anti-infectious regimen in kidney transplantation. Int. J. Technol. Assess. Health Care24(3), 312–317 (2008).
   PubMedGoogle Scholar
• Humar A, Lebranchu Y, Vincenti F et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant.10(5), 1228–1237 (2010).
   PubMed Web of Science ®Google Scholar
• Mitsani D, Nguyen MH, Kwak EJ et al. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis. J. Heart Lung Transplant.29(9), 1014–1020 (2010).
   PubMed Web of Science ®Google Scholar
• Meylan PR, Manuel O. Late-onset cytomegalovirus disease in patients with solid organ transplant. Curr. Opin. Infect. Dis.20(4), 412–418 (2007).
   PubMedGoogle Scholar
• Lamoth F, Manuel O, Venetz JP, Faouzi M, Meylan P, Pascual M. What is the impact of late-onset cytomegalovirus disease after valganciclovir prophylaxis in kidney transplantation? Transplantation86(9), 1323–1324 (2008).
   PubMedGoogle Scholar
• Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant.4(4), 611–620 (2004).
   PubMed Web of Science ®Google Scholar
• Arthurs SK, Eid AJ, Pedersen RA et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin. Infect. Dis.46(6), 840–846 (2008).
   PubMed Web of Science ®Google Scholar
• Limaye AP, Bakthavatsalam R, Kim HW et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation81(12), 1645–1652 (2006).
   PubMed Web of Science ®Google Scholar
• Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant.42(Suppl. 1), S70–S72 (2008).
   Google Scholar
• Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood113(23), 5711–5719 (2009).
   PubMed Web of Science ®Google Scholar
• Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev.22(1), 76–98 (2009).
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis.4(12), 725–738 (2004).
   PubMed Web of Science ®Google Scholar
• Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood78(5), 1373–1380 (1991).
   PubMed Web of Science ®Google Scholar
• Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood83(7), 1971–1979 (1994).
   PubMed Web of Science ®Google Scholar
• Crough T, Fazou C, Weiss J et al. Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8+ T-cell response. J. Virol.81(20), 11538–11542 (2007).
   PubMedGoogle Scholar
• Ljungman P, Aschan J, Azinge JN et al. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br. J. Haematol.83(1), 118–124 (1993).
   PubMed Web of Science ®Google Scholar
• Hebart H, Daginik S, Stevanovic S et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-γ-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood99(10), 3830–3837 (2002).
   PubMed Web of Science ®Google Scholar
• Sester U, Gartner BC, Wilkens H et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am. J. Transplant.5(6), 1483–1489 (2005).
   PubMed Web of Science ®Google Scholar
• Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann. Intern. Med.124(7), 633–642 (1996).
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron D, Mazeron MC, Chaput S et al. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS14(8), 1041–1049 (2000).
   PubMed Web of Science ®Google Scholar
• Steininger C, Puchhammer-Stockl E, Popow-Kraupp T. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J. Clin. Virol.37(1), 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• Humar A, Paya C, Pescovitz MD et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am. J. Transplant.4(4), 644–649 (2004).
   PubMedGoogle Scholar
• Humar A, Mazzulli T, Moussa G et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am. J. Transplant.5(5), 1065–1070 (2005).
   PubMed Web of Science ®Google Scholar
• Danziger-Isakov L, Heeger PS. Clinical utility of measuring T-cell immunity to CMV in transplant recipients. Am. J. Transplant.9(5), 987–988 (2009).
   PubMedGoogle Scholar
• Walker S, Fazou C, Crough T et al.Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl. Infect. Dis.9(2), 165–170 (2007).
   PubMed Web of Science ®Google Scholar
• Kumar D, Chernenko S, Moussa G et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant.9(5), 1214–1222 (2009).
   PubMed Web of Science ®Google Scholar
• Fleming T, Dunne J, Crowley B. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J. Med. Virol.82(3), 433–440 (2010).
   PubMedGoogle Scholar
• Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am. J. Transplant.8(8), 1749–1754 (2008).
   PubMed Web of Science ®Google Scholar
• Singh KP, Howard JL, Wild SP, Jones SL, Hoy J, Lewin SR. Human cytomegalovirus (CMV)-specific CD8+ T cell responses are reduced in HIV-infected individuals with a history of CMV disease despite CD4+ T cell recovery. Clin. Immunol.124(2), 200–206 (2007).
   PubMedGoogle Scholar
• Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J. Immunol.174(2), 1037–1045 (2005).
   PubMed Web of Science ®Google Scholar
• Eid AJ, Brown RA, Arthurs SK et al. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection. Transpl. Int.23(5), 506–513 (2010).
   PubMed Web of Science ®Google Scholar
• Egli A, Binet I, Binggeli S et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J. Transl. Med.6, 29 (2008).
   PubMedGoogle Scholar
• Sester M, Sester U, Gartner B et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation71(9), 1287–1294 (2001).
   PubMed Web of Science ®Google Scholar
• Bunde T, Kirchner A, Hoffmeister B et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J. Exp. Med.201(7), 1031–1036 (2005).
   PubMed Web of Science ®Google Scholar
• Gerna G, Lilleri D, Fornara C et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am. J. Transplant.6(10), 2356–2364 (2006).
   PubMed Web of Science ®Google Scholar
• Radha R, Jordan S, Puliyanda D et al. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am. J. Transplant.5(1), 110–117 (2005).
   PubMedGoogle Scholar
• Shlobin OA, West EE, Lechtzin N et al. Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J. Immunol.176(4), 2625–2634 (2006).
   PubMedGoogle Scholar
• Jacobson MA, Maecker HT, Orr PL et al. Results of a cytomegalovirus (CMV)-specific CD8+/interferon-γ+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. J. Infect. Dis.189(8), 1362–1373 (2004).
   PubMedGoogle Scholar
• Weinberg A, Wohl DA, MaWhinney S et al. Cytomegalovirus-specific IFN-γ production is associated with protection against cytomegalovirus reactivation in HIV-infected patients on highly active antiretroviral therapy. AIDS17(17), 2445–2450 (2003).
   PubMedGoogle Scholar
• Mattes FM, Vargas A, Kopycinski J et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am. J. Transplant.8(5), 990–999 (2008).
   PubMedGoogle Scholar
• Weinberg A, Tierney C, Kendall MA et al. Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy. J. Infect. Dis.193(4), 488–493 (2006).
   PubMed Web of Science ®Google Scholar
• Gratama JW, Boeckh M, Nakamura R et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood116(10), 1655–1662 (2010).
   PubMed Web of Science ®Google Scholar
• Crough T, Fazou C, Weiss J et al. Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8+ T-cell response. J. Virol.81(20), 11538–11542 (2007).
   PubMedGoogle Scholar
• Cervera C, Lozano F, Saval N et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation83(11), 1493–1500 (2007).
   PubMedGoogle Scholar
• Manuel O, Pascual M, Trendelenburg M, Meylan PR. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation83(3), 359–362 (2007).
   PubMedGoogle Scholar